DrugPatentWatch Database Preview
Drugs in Development Information for SGI-1776
Drug Development Status for SGI-1776: Sponsors, patents, clinical trial progress
SGI-1776 is an investigational drug.
There have been 26 clinical trials for SGI-1776.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Astex Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are two US patents protecting this investigational drug and sixteen international patents.
Summary for SGI-1776
| US Patents | 2 |
| International Patents | 16 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2017-02-01) |
| Vendors | 64 |
Recent Clinical Trials for SGI-1776
| Title | Sponsor | Phase |
|---|---|---|
| Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Astex Pharmaceuticals | Phase 1/Phase 2 |
| Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Bristol-Myers Squibb | Phase 1/Phase 2 |
| Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for SGI-1776
Top disease conditions for SGI-1776
Top clinical trial sponsors for SGI-1776
US Patents for SGI-1776
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SGI-1776 | Start Trial | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SuperGen, Inc. (Dublin, CA) | Start Trial |
| SGI-1776 | Start Trial | Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitors | Tolero Pharmaceuticals, Inc. (Salt Lake City, UT) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SGI-1776
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SGI-1776 | Australia | 2007316417 | 2026-11-06 | Start Trial |
| SGI-1776 | Brazil | PI0718029 | 2026-11-06 | Start Trial |
| SGI-1776 | Canada | 2667487 | 2026-11-06 | Start Trial |
| SGI-1776 | China | 101600718 | 2026-11-06 | Start Trial |
| SGI-1776 | European Patent Office | 2086979 | 2026-11-06 | Start Trial |
| SGI-1776 | Japan | 2010509242 | 2026-11-06 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
